654 related articles for article (PubMed ID: 27106604)
1. Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles.
Youssef MA; Abou-Setta AM; Lam WS
Cochrane Database Syst Rev; 2016 Apr; 4(4):CD003719. PubMed ID: 27106604
[TBL] [Abstract][Full Text] [Related]
2. Recombinant versus urinary human chorionic gonadotrophin for final oocyte maturation triggering in IVF and ICSI cycles.
Youssef MA; Al-Inany HG; Aboulghar M; Mansour R; Abou-Setta AM
Cochrane Database Syst Rev; 2011 Apr; (4):CD003719. PubMed ID: 21491386
[TBL] [Abstract][Full Text] [Related]
3. Recombinant versus urinary human chorionic gonadotrophin for ovulation induction in assisted conception.
Al-Inany HG; Aboulghar M; Mansour R; Proctor M
Cochrane Database Syst Rev; 2005 Apr; (2):CD003719. PubMed ID: 15846677
[TBL] [Abstract][Full Text] [Related]
4. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology.
Youssef MA; Van der Veen F; Al-Inany HG; Mochtar MH; Griesinger G; Nagi Mohesen M; Aboulfoutouh I; van Wely M
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD008046. PubMed ID: 25358904
[TBL] [Abstract][Full Text] [Related]
5. Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles.
Mochtar MH; Danhof NA; Ayeleke RO; Van der Veen F; van Wely M
Cochrane Database Syst Rev; 2017 May; 5(5):CD005070. PubMed ID: 28537052
[TBL] [Abstract][Full Text] [Related]
6. Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction.
Siristatidis CS; Gibreel A; Basios G; Maheshwari A; Bhattacharya S
Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD006919. PubMed ID: 26558801
[TBL] [Abstract][Full Text] [Related]
7. Recombinant versus urinary gonadotrophins for triggering ovulation in assisted conception.
Al-Inany H; Aboulghar MA; Mansour RT; Proctor M
Hum Reprod; 2005 Aug; 20(8):2061-73. PubMed ID: 16024539
[TBL] [Abstract][Full Text] [Related]
8. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles.
Youssef MA; Van der Veen F; Al-Inany HG; Griesinger G; Mochtar MH; Aboulfoutouh I; Khattab SM; van Wely M
Cochrane Database Syst Rev; 2011 Jan; (1):CD008046. PubMed ID: 21249699
[TBL] [Abstract][Full Text] [Related]
9. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles.
Youssef MA; Van der Veen F; Al-Inany HG; Griesinger G; Mochtar MH; van Wely M
Cochrane Database Syst Rev; 2010 Nov; (11):CD008046. PubMed ID: 21069701
[TBL] [Abstract][Full Text] [Related]
10. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology.
Al-Inany HG; Youssef MA; Ayeleke RO; Brown J; Lam WS; Broekmans FJ
Cochrane Database Syst Rev; 2016 Apr; 4(4):CD001750. PubMed ID: 27126581
[TBL] [Abstract][Full Text] [Related]
11. Oral medications including clomiphene citrate or aromatase inhibitors with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilisation.
Kamath MS; Maheshwari A; Bhattacharya S; Lor KY; Gibreel A
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD008528. PubMed ID: 29096046
[TBL] [Abstract][Full Text] [Related]
12. Luteal phase support for assisted reproduction cycles.
van der Linden M; Buckingham K; Farquhar C; Kremer JA; Metwally M
Cochrane Database Syst Rev; 2015 Jul; 2015(7):CD009154. PubMed ID: 26148507
[TBL] [Abstract][Full Text] [Related]
13. Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI).
Lensen SF; Wilkinson J; Leijdekkers JA; La Marca A; Mol BWJ; Marjoribanks J; Torrance H; Broekmans FJ
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD012693. PubMed ID: 29388198
[TBL] [Abstract][Full Text] [Related]
14. In vitro fertilisation for unexplained subfertility.
Pandian Z; Gibreel A; Bhattacharya S
Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD003357. PubMed ID: 26583517
[TBL] [Abstract][Full Text] [Related]
15. Assisted reproductive technologies for male subfertility.
Cissen M; Bensdorp A; Cohlen BJ; Repping S; de Bruin JP; van Wely M
Cochrane Database Syst Rev; 2016 Feb; 2(2):CD000360. PubMed ID: 26915339
[TBL] [Abstract][Full Text] [Related]
16. Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome.
D'Angelo A; Amso NN; Hassan R
Cochrane Database Syst Rev; 2017 May; 5(5):CD002811. PubMed ID: 28535578
[TBL] [Abstract][Full Text] [Related]
17. Oral contraceptive pill, progestogen or oestrogen pretreatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques.
Farquhar C; Rombauts L; Kremer JA; Lethaby A; Ayeleke RO
Cochrane Database Syst Rev; 2017 May; 5(5):CD006109. PubMed ID: 28540977
[TBL] [Abstract][Full Text] [Related]
18. Volume expanders for the prevention of ovarian hyperstimulation syndrome.
Youssef MA; Mourad S
Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD001302. PubMed ID: 27577848
[TBL] [Abstract][Full Text] [Related]
19. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome.
Tso LO; Costello MF; Albuquerque LET; Andriolo RB; Macedo CR
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD006105. PubMed ID: 33347618
[TBL] [Abstract][Full Text] [Related]
20. Human chorionic gonadotrophin priming for fertility treatment with in vitro maturation.
Reavey J; Vincent K; Child T; Granne IE
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD008720. PubMed ID: 27852101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
